Booth L et al.PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.Oncotarget 8:1449-1468 (2017).
Booth L et al.The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.Oncotarget 8:16367-16386 (2017).
Booth L et al.PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].Oncotarget 8:13464-13475 (2017).
Booth L et al.HDAC inhibitors enhance the immunotherapy response of melanoma cells.Oncotarget 8:83155-83170 (2017).
Booth L et al.Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.Oncotarget 7:12975-96 (2016).
Tavallai M et al.Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.Front Oncol 6:142 (2016).
Booth L et al.[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NF?B compensatory survival signaling.Oncotarget 7:23608-32 (2016).
Booth L et al.Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.Oncotarget 7:40398-40417 (2016).